# US 2008/0188472 A1 · Indole-2-Carboxylic Acid Hydrazides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188472 A1
- Document ID: US20080188472A1
- Status: Published application
- Kind: A1
- Application number: 10/592,011
- Filed: 2005-03-08
- Published: 2008-08-07
- Earliest claimed: 2004-03-08
- Assignees: Prosidion Limited
- Inventors: Stuart Edward Bradley; Revathy Perpetua Jeevaratnam; Thomas Martin Krulle; Martin James Procter; Robert John Rowley; Gerard Hugh Thomas; Ana Valdes
- Web page: https://patentgrep.com/patent/US20080188472A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 35/00: Antineoplastic agents
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia, e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
Y is —C(O)—, —S(O)2—, or —C(NH)—;
Z is C1-4alkylene, oxygen, —(CH2)mO—, —O(CH2)m—, —NR—, —(CH2)mNR—, —NR(CH2)m—, —(CH2)mS(O)2—, or a bond;
m is 1, 2, 3, or 4;
R is C0-4alkyl, C0-4alkylaryl, or C0-4alkylhetoraryl;
R1 and R1′ are each independently, halogen, hydroxy, cyano, C0-4alkyl, C1-4alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, ethenyl, or ethynyl;
R2 is C0-4alkyl, COOR6, COR6, C1-4alkoxyC1-4alkyl-, hydroxyC1-4alkyl-, cycloalkylC0-4alkyl-, arylC0-4alkyl-, or hetarylC0-4alkyl-, wherein any of the aryl or hetaryl rings are optionally substituted with 1-2 independent halogen, cyano, C1-4alkyl, C1-4alkoxy, —N(C0-4alkyl)(C0-4alkyl), —SO2C1-4alkyl, —SO2N(C0-4alkyl)(C0-4alkyl), hydroxy, fluoromethyl, difluoromethyl, or trifluoromethyl substituents;
R3 is hydrogen, —COOC0-4alkyl, C1-4alkoxy, C1-4alkyl, arylC1-4alkylthio-, —C0-4alkylaryl, —C0-4alkylhetaryl, —C0-4alkylcycloalkyl, or —C0-4alkylheterocyclyl, wherein any of the rings is optionally substituted with 1-3 independent halogen, cyano, C1-4alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, —C0-4alkylNHC(O)O(C1-4alkyl), —C0-4alkylNR7R8, —C(O)R9, C1-4alkoxyCO4alkyl-, —COOC0-4alkyl, O—C4alkylNHC(O)R9, —C0-4alkylC(O)N(R10)2, —C1-4alkoxyC1-4alkoxy, hydroxyC0-4alkyl-, —NHSO2R10, —SO2(C1-4alkyl), —SO2NR11R12, 5- to 6-membered heterocyclyl, phenylC0-2alkoxy, or phenylC0-2alkyl substituents, wherein phenyl is optionally substituted with 1-2 independent halogen, cyano, C1-4alkyl, C1-4alkoxy, —N(C0-4alkyl)(C0-4alkyl), —SO2C1-4alkyl, —SO2N(C0-4alkyl)(C0-4alkyl), hydroxy, fluoromethyl, difluoromethyl, or trifluoromethyl substituents, or two bonds on a ring carbon of the heterocyclyl group optionally can form an oxo (═O) substituent;
or R3 is —NR4(—C0-4alkylR5);
R4 is C0-3alkyl, —C2-3alkyl-NR7R8, C3-6cycloalkyl optionally substituted by hydroxyC0-4alkyl- further optionally substituted by hydroxy, C1-2alkoxyC2-4alkyl-, or C1-2alkyl-S(O)n—C2-3alkyl-;
n is 0, 1, or 2;
R5 is hydrogen, hydroxyC2-3alkyl-, C1-2alkoxyCO4alkyl-, or aryl, hetaryl, or heterocyclyl;
wherein a heterocyclic nitrogen-containing R5 ring optionally is mono-substituted on the ring nitrogen with C1-4alkyl, benzyl, benzoyl, C1-4alkyl-C(O), —SO2C1-4alkyl, —SO2N(C0-4alkyl)(C0-4alkyl), C1-4alkoxycarbonyl, or aryl(C1-4alkoxy)carbonyl; and wherein the R5 rings are optionally mono-substituted on a ring carbon with halogen, cyano, C1-4alkyl-C(O), C1-4alkyl-SO2—, C1-4alkyl, C1-4alkoxy, hydroxy, —N(C0-4alkyl)(C0-4alkyl), hydroxyC0-4alkyl-, or C0-4alkylcarbamoyl-, provided that no quaternised nitrogen is included; or two bonds on a ring carbon of the heterocycle optionally can form an oxo (═O) substituent;
R6 is C1-4alkyl, aryl, or hetaryl;
R7 and R3 are independently C0-4alkyl, C3-6cycloalkyl, or CO(C1-4alkyl);
R9 is C1-4alkyl, or C3-6cycloalkyl;
R10 is C0-4alkyl, or C3-6cycloalkyl; and
R11 and R12 are independently C0-4alkyl or together with the nitrogen to which they are attached may form a 4- to 6-membered heterocycle;
provided there are no nitrogen-oxygen, nitrogen-nitrogen, oxygen-oxygen or nitrogen-halogen bonds in the grouping —Y-Z-R3; and
provided that when —Y-Z- represents —C(O)—, —C(NH)—, —C(O)—C1-4alkylene, —C(NH)—C1-4alkylene, —C(O)—NR—, —C(NH)—NR—, —C(O)—(CH2)mNR—, or —C(NH)—(CH2)mNR—, then R3 is not optionally substituted C3-10cycloalkyl, C5-10cycloalkenyl, phenyl, naphthyl, pyridyl, pyrazinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, furanyl, thiophenyl, pyrrolyl, pyrrolidinyl, piperidinyl, indolyl, benzo[1,3]dioxol, thieno[2,3-b]pyrrolyl, or thieno[3,2-b]pyrrolyl.

### Claim 2 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is —C(O)— or —S(O)2—.

### Claim at position 3

3-14. (canceled)

### Claim 15 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is C1-4alkylene, oxygen, —(CH2)mO—, —NR— or a bond.

### Claim 16 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is —C(O)—.

### Claim 17 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is —S(O)2—.

### Claim 18 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 and R1′ are each independently, hydrogen or halogen.

### Claim 19 (depends on 18)

A compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein one of R1 and R1′ is hydrogen and the other is 5-chloro.

### Claim 20 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen.

### Claim 21

A compound selected from
or a pharmaceutically acceptable salt thereof.

### Claim 22

A compound selected from
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 1)

A method for the treatment of a disease or condition in which glycogen phosphorylase plays a role comprising a step of administering to a subject in need thereof an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

A method for the treatment of hyperglycemia or diabetes comprising a step of administering to a subject in need thereof an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

A method for the prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering to a subject in need thereof an effective prophylactic amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

A method for the treatment of hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia, or achieving cardioprotection or inhibition of abnormal cell growth, comprising a step of administering to a subject in need thereof an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
